Skip to Content

Vascular Biogenics Ltd.

Merger

  • Date:
  • 2/23/2023
  • Company Name:
  • Vascular Biogenics Ltd.
  • Stock Symbol:
  • VBLT
  • Company Name - Buyer:
  • Notable Labs, Inc.
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 2/23/2023

Case Finder

Locate any case using the tools below.

NEW YORK, February 23, 2023 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Vascular Biogenics Ltd. (NASDAQ: VBLT) (“VBL Therapeutics”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Notable Labs, Inc. (“Notable”).

On February 23, 2023, VBL Therapeutics announced that it had entered into an agreement to be acquired by Notable in a $115.9 million all-stock deal. Pursuant to the merger agreement, Notable stockholders are expected to own approximately 76% and VBL Therapeutics shareholders are expected to own approximately 24% of the combined company, each on a fully-diluted basis and subject to adjustment. The deal is expected to close in the second quarter of 2023.

Bragar Eagel & Squire is concerned that VBL Therapeutics’ board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for VBL Therapeutics’ stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Vascular Biogenics Ltd.. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: